What this site will and will not claim.

Regulatory claims prefer the agency that made the decision. Approved-product claims prefer the product’s own label, and this revision often stops at the fact of approval plus the indication already checked, rather than retyping an entire prescribing information packet. Trial claims prefer the paper. A PubMed search page is not a paper, so those stand-ins were removed.

A record needs a DOI, a PMID, an NCT number, or an agency URL. If it does not, it stays out. Preprints would be marked as not peer-reviewed. None are indexed. Anecdotes on the compound pages are labeled as reports, not rates.

• Demonstrated: the cited source shows that statement.
• Preliminary: the source is real, and the inference is still thin.
• Unsupported: the claim is circulating without a source in this index.
• Not established: we have not verified a source. The literature might still exist.

There is no evidence percentage, and no score that ranks one molecule above another. Missing from this library is not the same sentence as “nobody has studied it.”

Most of the 25 profiles do not have three verified sources. Several have none. That is a limit of this revision, not a claim that those compounds are unstudied, and not a claim that they are safe. Identity rows carried forward from earlier pages are published reference values. They were not re-derived from spectra here. A certificate of analysis on a real lot overrides them.

Content that names a paper was checked against that paper or the agency page. The review date 2026-11-07 means that comparison. It does not mean a clinician signed the page. AI-assisted drafting was used. Verification is the citation, not the fact that a model wrote a sentence.

• 2026-11-07

  Forzinity is not a longevity approval

  SS-31 / elamipretide: FDA accelerated approval of Forzinity on 19 September 2025, for muscle strength in Barth syndrome at 30 kg and above. Research vials are not that product.

• 2026-11-07

  BPC-157 review, with a cutoff

  Poolton, Minett, and Kazmi, Acta Orthop Belg, online 8 October 2026, PMID 42885452. Search through 1 June 2026: three studies, 30 participants, very low certainty. The count is not an eternal fact.

• 2026-11-07

  TRIUMPH-1 dates and primary comparisons

  Retatrutide phase 3, NEJM, PMID 42814954. Online 29 September 2026, issue 5 November 2026. Primary comparisons were 9 mg and 12 mg versus placebo. The paper is not an approval.

• 2026-11-07

  CJC names are not interchangeable

  The FDA naming note at fda.gov/media/183819 is indexed. With DAC, without DAC, and modified GRF(1-29) stay separate. There is no with-DAC profile, because a second empty page would pretend we had one.

• 2026-11-07

  Search pages are not papers

  PubMed search-result links that stood in for unidentified trials were removed. Tirzepatide, tesamorelin, and bremelanotide still have regulatory notes. They do not have a fake citation.

• 2026-11-07

  No universal freezer rule and no 28-day rule

  Handling no longer states one storage ritual for every compound. Catalog storage lines on profiles are labeled as catalog convention, not a stability study.

These were considered and left out, rather than published as empty profiles.

• CJC-1295 with DAC, as its own profile, once a sequence and a source are in hand
• GHRP-2, GHRP-6, hexarelin
• Full-length thymosin β4, separate from the TB-500 fragment
• Liraglutide and the other approved incretins not already in the 25
• Oxytocin, setmelanotide, teduglutide

Also deferred: a light theme, live calls to PubMed on every page, and nine of the fifteen teaching essays. The six that are finished are in Learn.

There is no inbox wired up, so this does not submit anything. It copies a note you can paste to whoever keeps the site. Don’t include personal medical records.